

Introducing the

EXPERT COLLECTION

The Taylor & Francis Expert Collection is the world's largest series of review journals in research, development, and clinical medicine.

The Expert Collection is comprised of 29 peer-reviewed journals combining the well-established Expert Opinion and Expert Review series into one essential and comprehensive collection.

What makes the Expert Collection different?

The Expert Collection combines the personal opinions of our expert authors who are all internationally recognized experts in their fields. They provide their insights about where research is now, where it should go next and how it should get there. In this respect, all Expert Collection reviews end with an expert opinion or an expert commentary, not a conclusion.

The Expert Collection publishes:

- Reviews
- Editorials
- Original research
- Drug evaluations
- Treatment evaluations
- Clinical trial evaluations
- Technology evaluations
- Patent evaluations
- Key paper evaluations
- Perspectives
- Special reports
- Mini reviews
- Letters to Editor
- Multimedia offering
- Video abstracts


“In my opinion, the Expert Collection is the most relevant journal review series in the area of Pharmacology. The Expert Collection is a credible, topical, and scholarly resource that I have come to rely on in my role as a leader of international pharmacological studies. It is apparent that the peer review process is thorough and critical, and the editorial process is unparalleled in terms of author support.”

Dr Roger McIntyre, *University of Toronto*, Editor-in-Chief
Expert Opinion on Drug Safety

The Expert Opinion journals cover the entire R&D pipeline across 11 journals



The Expert Review journals cover 18 different areas of clinical medicine



The Expert Review Series

						
Journal	Expert Review of Anticancer Therapy	Expert Review of Anti-infective Therapy	Expert Review of Cardiovascular Therapy	Expert Review of Clinical Immunology	Expert Review of Clinical Pharmacology	Expert Review of Endocrinology & Metabolism
Impact Factor	2.212	3.139	–	3.27	2.932	–
Scope	Appraisal and commentary on the major trends in cancer care and highlights on the performance of new therapeutic and diagnostic approaches.	Therapeutics and diagnostics in the treatment of infectious disease.	Evaluation of new diagnostic and therapeutic cardiovascular modalities.	Performance of new therapeutic and diagnostic modalities in clinical immunology.	Critical analysis of safety, tolerability, efficacy and therapeutic applications of new therapies.	Extensive coverage of research and clinical advancements in the field of endocrine control, metabolism and novel therapeutics.
Medline indexed?	Yes	Yes	Yes	Yes	Yes	–
						
Journal	Expert Review of Gastroenterology & Hepatology	Expert Review of Hematology	Expert Review of Medical Devices	Expert Review of Molecular Diagnostics	Expert Review of Neurotherapeutics	Expert Review of Ophthalmology
Impact Factor	2.743	2.246	2.228	3.1	3.149	–
Scope	Latest advances in pathological, biochemical and physiological understanding of diseases affecting the gastrointestinal tract and liver.	Commentary and analysis to elucidate best clinical practice in hematology.	Commentary, analysis, and debate on the development, testing, and clinical use of devices.	Latest advances in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease.	Analysis of drugs and medicines in clinical neurology and neuropsychiatry.	Commentary and debate on current and emerging approaches in ocular medicine.
Medline indexed?	Yes	Yes	Yes	Yes	Yes	–
						
Journal	Expert Review of Pharmacoeconomics & Outcomes Research	Expert Review of Proteomics	Expert Review of Precision Medicine & Drug Development	Expert Review of Quality of Life in Cancer Care	Expert Review of Respiratory Medicine	Expert Review of Vaccines
Impact Factor	1.78	3.849	–	–	2.432	3.555
Scope	Cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches.	Technologies, methods, and discoveries from the field of proteomics.	Original research and review articles covering the development and clinical application of medicine to be used in a personalized therapy setting.	Discussion of the major topics of concern in the quality of life of cancer patients, and how best to manage these issues in the clinical setting.	Commentary from international leaders in the fields of obstructive, restrictive, vascular, and infectious respiratory diseases.	Analysis of the clinical effectiveness of new vaccines plus new developments in vaccine technology.
Medline indexed?	Yes	Yes	–	–	Yes	Yes

The Expert Opinion Series

DRUG DISCOVERY

PRECLINICAL

PHASE I

						
Journal	Expert Opinion on Therapeutic Patents	Expert Opinion on Drug Discovery	Expert Opinion on Therapeutic Targets	Expert Opinion on Investigational Drugs	Expert Opinion on Biological Therapy	Expert Opinion on Orphan Drugs
Impact Factor	3.041	3.876	4.873	4.030	3.684	0.559
Scope	Technological advances and developments in pharmaceutical patents, with a strong medicinal chemistry focus.	Novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates.	Novel molecular drug targets and their potential for drug discovery/disease treatment.	Drugs and drug classes in early phase I/II clinical development.	Discovery, development, and clinical application of vaccines, antibodies, stem cells, genetic therapies, and hormone or protein-based therapies.	Research and development on rare diseases and orphan drugs.
Medline indexed?	Yes	Yes	Yes	Yes	Yes	—

PHASE II

PHASE III

LAUNCH

					
Journal	Expert Opinion on Drug Delivery	Expert Opinion on Drug Metabolism & Toxicology	Expert Opinion on Emerging Drugs	Expert Opinion on Pharmacotherapy	Expert Opinion on Drug Safety
Impact Factor	5.657	3.027	3.062	3.894	3.439
Scope	Drug delivery technologies and new drug formulations.	Approaches to the ADME-Tox arena, as well as metabolic, pharmacokinetic, and toxicological issues relating to specific drugs or drug classes.	Focus on drugs coming up through the pipeline, analysis on what the next drugs to come on to the market are likely to be and their impact on disease management.	Newly approved or near to launch drugs and drug classes.	Post-marketing and pharmacovigilance studies as well as the safety and adverse event profiles of marketed drugs.
Medline indexed?	Yes	Yes	Yes	Yes	Yes

* Impact Factors from 2016 Journal Citation Reports® (Clarivate Analytics©, 2017)

Our Ethics

Quick Facts

All Expert Collection titles are members of the Committee on Publication Ethics (COPE)

Committee on Publication Ethics (COPE)

The Committee on Publication Ethics (COPE) is a charity registered in the UK. With over 7,000 members, it is concerned with the integrity of peer-reviewed publications in science, particularly biomedicine. COPE provides a forum for publishers and editors of scientific journals to discuss issues relating to the integrity of the work submitted to or published in their journals.



All Expert Collection titles are independently peer-reviewed and require full author disclosures

Supported by industry experts, we remain vigilant against abuses in every title we publish.

Our content influences patient care decisions. With this comes enormous responsibility to safeguard the medical community from fraudulent or misleading data. We not only follow industry standards of publication ethics, but have taken a leading role in pushing them further.

In 2003, our sister journal, *Current Medical Research & Opinion (CMRO)* published the first Good Publication Practice (GPP) guidelines. The aim of the guidelines was to ensure that clinical trials sponsored by pharmaceutical companies were published in a responsible and ethical manner. The guidelines quickly established a common standard for all industry-sponsored research and continue to do so today.

We continue to take an active role in organizations that endorse publication ethics. In January 2010, we joined COPE.

The Expert Collection adheres to the principles of Uniform Requirements for Manuscripts Submitted in Biomedical Journals, prepared by the ICMJE and the NLM guidelines for published articles and supplements

Uniform Requirements for Manuscripts Submitted to Biomedical Journals

Created by the International Committee of Medical Journal Editors (ICMJE), the Uniform Requirements address the ethical principles related to the process of evaluating, improving, and publishing manuscripts in biomedical journals, and the relationship among editors and authors, peer reviewers, and the media.

A copy of the most recent Uniform Requirements can be found at www.icjme.org.

Author Services

Accelerated Publication

For time-sensitive research. Fast Track ensures publication within 3-5 weeks and Rapid Track ensures your work is published within 5-7 weeks.

Reprints & ePrints

Clinical content published in Taylor & Francis journals can help you demonstrate the benefits of your products to your customers.

Supplements

Targeted, cost-effective and high-impact reach, connecting the topical and timely knowledge from your network of key opinion leaders with our global readership.

Subscription options for the Expert Collection

Expert Review Collection

A package including 18 of the Expert Review series journals.

Expert Opinion Collection

A package including 11 of the Expert Opinion series journals.



Title-by-title subscriptions

Tailor your collection on a title-by-title basis. You can choose from combined print and online access or opt for online only access.

Discover the Taylor & Francis Medical Library

The Medical Library provides online access to a broad range of journal content in over 30 key subject areas. This collection includes current content from over 200 peer-reviewed academic journals.

HIGHLIGHTS...



EDITORIAL CONTACT

Mary Yianni, Publisher, Expert Collection

Mary.Yianni@informa.com • Tel: +44 (0)207 017 7783

